Compare CATO & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | MNOV |
|---|---|---|
| Founded | 1946 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 68.4M |
| IPO Year | 1994 | 2004 |
| Metric | CATO | MNOV |
|---|---|---|
| Price | $2.66 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 164.1K | 37.2K |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $653,812,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | $5.89 | ★ N/A |
| Revenue Growth | 0.62 | ★ 194.15 |
| 52 Week Low | $2.59 | $1.17 |
| 52 Week High | $4.92 | $1.96 |
| Indicator | CATO | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 35.07 | 56.54 |
| Support Level | N/A | $1.27 |
| Resistance Level | $3.62 | $1.55 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 4.87 | 49.98 |
The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.